0001140361-21-037655.txt : 20211112 0001140361-21-037655.hdr.sgml : 20211112 20211112161621 ACCESSION NUMBER: 0001140361-21-037655 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211109 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malier Vanessa CENTRAL INDEX KEY: 0001891515 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41008 FILM NUMBER: 211403713 MAIL ADDRESS: STREET 1: 1209 ORANGE STREET CITY: WILLMINGTON STATE: DE ZIP: 19801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IO Biotech, Inc. CENTRAL INDEX KEY: 0001865494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870909276 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 BUSINESS PHONE: 4570702980 MAIL ADDRESS: STREET 1: OLE MAALOES VEH 3 CITY: COPENHAGEN STATE: G7 ZIP: 2200 4 1 form4.xml FORM 4 X0306 4 2021-11-09 0001865494 IO Biotech, Inc. IOBT 0001891515 Malier Vanessa C/O IO BIOTECH, INC. OLE MAALOES VEH 3 COPENHAGEN G7 2200 DENMARK true Common Stock 2021-11-09 4 C 0 796059 A 796059 I See footnote Common Stock 2021-11-09 4 C 0 267977 A 267977 I See footnote Common Stock 2021-11-09 4 P 0 162500 14 A 958559 I See footnote Common Stock 2021-11-09 4 P 0 162500 14 A 430477 I See footnote Series C Preferred Stock 2021-11-09 4 C 0 63350 0 D Common Stock 796059 0 I See footnote Series C Preferred Stock 2021-11-09 4 C 0 21325 0 D Common Stock 267977 0 I See footnote Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. /s/ Brian Burkavage, Attorney-in-Fact for Vanessa Malier 2021-11-12